This work was supported by the National Key R&D Program of China (number 2019YFE0190500); study on the mechanism of MiR-3188 targeting mTOR signaling in the regulation of Imatinib in gastrointestinal stromal tumors (number 2016JC2048); establishment and application of comprehensive intervention demonstration system for hereditary tumors (number 2017SK103); the Natural Science Foundation of China Hunan Science & Technology Department (number 2019JJ40429) and Science and Health Joint Project of Natural Science Foundation of Hunan Province (number 2018JJ6048). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.